Impact of Vitamin D on Chronic Kidney Diseases in Non-Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials
Open Access
- 23 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4), e61387
- https://doi.org/10.1371/journal.pone.0061387
Abstract
Recent studies have supported a role for both newer and more established vitamin D compounds in improving proteinuria, although systematic evaluation is lacking. Furthermore, concerns remain regarding the influence of vitamin D on the progression of renal function. We analyzed the efficacy and safety of vitamin D in non-dialysis patients and compared the use of newer versus established vitamin D compounds by performing a meta-analysis of randomized controlled trials. A literature search of PubMed (1975 to September, 2012), EMBASE.com (1966 to September, 2012) and Ovid EBM Reviews (through September, 2012) was conducted. Eighteen studies were eligible for final inclusion; of these, six explored the effects of vitamin D on proteinuria, twelve studied the effects of supplementation on renal function, and fifteen discussed the incidence of hypercalcemia. Compared to the placebo or no interference, both the newer and established vitamin D sterols reduced proteinuria to a similar extent (RR, 2.00; 95% CI, 1.42 to 2.81). No decrease in the glomerular filter rate was observed (SMD, −0.10; 95%CI, −0.24 to 0.03), and the risk for dialysis initiation was 1.48 (95% CI, 0.54 to 4.03) with vitamin D treatment. Additionally, there was an increased risk of hypercalcemia for patients treated with either newer or established vitamin D compounds as compared with the controls (RR, 4.78; 95% CI, 2.20 to 10.37). The head-to-head studies showed no differences in the effects of either newer or established compounds on proteinuria or the risk of hypercalcemia. No serious adverse events were associated with the administration of vitamin D. Vitamin D therapy appears to decrease proteinuria and have no negative influence on renal function in non-dialysis patients. But the occurrence of hypercalcemia should be evaluated when vitamin D is provided. No superiority for newer versus established vitamin D analogue is found.This publication has 42 references indexed in Scilit:
- An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease.2012
- Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney DiseaseJAMA, 2012
- Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy TrialKidney International, 2004
- Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN)Kidney International, 2004
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With NephropathyCirculation, 2004
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4American Journal of Kidney Diseases, 2004
- Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failureNephrology Dialysis Transplantation, 2004
- Low Dose CalcitriolVersusPlacebo in Patients with Predialysis Chronic Renal Failure*Journal of Clinical Endocrinology & Metabolism, 1988
- DETERIORATION OF RENAL FUNCTION DURING TREATMENT OF CHRONIC RENAL FAILURE WITH 1,25- DIHYDROXYCHOLECALCIFEROLThe Lancet, 1978